Anaptys pockets $33.9M in second VC round

Anaptys Biosciences has raised $33.9 million in its second venture round. The San Diego-based biotech garnered money from Novo A/S, Frazier Healthcare Ventures, Alloy Ventures, and Avalon Ventures. Much of that money will be put to use advancing the company's technology for antibody development and optimization.

- check out the release for more

ALSO: Piedmont Pharmaceuticals has secured $8.5 million in Series B financing from CM Capital Investments of Brisbane, Australia, and other investors. Release

PLUS: Cambridge, MA-based Ensemble Discovery, a developer of a DNA-programmed chemistry platform for developing therapeutics and bioassays, has raised $15 million in Series B funding. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me